<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OTO</journal-id>
<journal-id journal-id-type="hwp">spoto</journal-id>
<journal-title>Otolaryngology–Head and Neck Surgery</journal-title>
<issn pub-type="ppub">0194-5998</issn>
<issn pub-type="epub">1097-6817</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0194599811434890</article-id>
<article-id pub-id-type="publisher-id">10.1177_0194599811434890</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Head and Neck Surgery</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Effects of Functional Polymorphisms in the <italic>TGFβ1</italic> Gene on Nasopharyngeal Carcinoma Susceptibility</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Hu</surname><given-names>Sunhong</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0194599811434890">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhou</surname><given-names>Guojin</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0194599811434890">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhang</surname><given-names>Lei</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0194599811434890">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Jiang</surname><given-names>Huifen</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0194599811434890">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Xiao</surname><given-names>Mang</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0194599811434890">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0194599811434890"><label>1</label>Department of Otorhinolaryngology–Head and Neck Surgery, Sir Run Run Shaw Hospital, Key Laboratory of Biotherapy of Zhejiang province, Zhejiang University, Hangzhou, China</aff>
<aff id="aff2-0194599811434890"><label>2</label>Department of Clinical Laboratory, Zhejiang Cancer Hospital, Hangzhou, China</aff>
<author-notes>
<corresp id="corresp1-0194599811434890">Mang Xiao, MD, Department of Otorhinolaryngology–Head and Neck Surgery, Sir Run Run Shaw Hospital, Key Laboratory of Biotherapy of Zhejiang province, Zhejiang University, Hangzhou, China Email: <email>joelxm@hotmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>146</volume>
<issue>4</issue>
<fpage>579</fpage>
<lpage>584</lpage>
<history>
<date date-type="received">
<day>11</day>
<month>10</month>
<year>2011</year>
</date>
<date date-type="received">
<day>6</day>
<month>12</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>13</day>
<month>12</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© American Academy of Otolaryngology—Head and Neck Surgery Foundation 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">Official journal of the American Academy of Otolaryngology–Head and Neck Surgery Foundation</copyright-holder>
</permissions>
<abstract>
<p><italic>Objective</italic>. Transforming growth factor β1 (TGFβ1) promotes tumor growth and metastasis in the later stage of cancer development. In this study, we explored whether <italic>TGFβ1</italic> polymorphisms were associated with increased risk of nasopharyngeal carcinoma (NPC) in a Chinese population.</p>
<p><italic>Design</italic>. Case-control study.</p>
<p><italic>Setting</italic>. Hospitals of the Department of Otorhinolaryngology–Head and Neck Surgery.</p>
<p><italic>Subjects and Methods</italic>. Two single nucleotide polymorphisms of <italic>TGFβ1</italic> gene promoter -509C/T (rs1800469) and 869T/C (Leu 10 Pro, rs1800470) at exon 1 were analyzed in 522 NPC patients and 712 age- and sex-matched controls in a Chinese population, using polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP) analysis. Functional relevance of the polymorphism was determined by biochemical assays.</p>
<p><italic>Results</italic>. The -509T allele carriers were associated with a significantly reduced risk of NPC as compared with the noncarriers (odds ratio [OR], 0.67; 95% confidence interval [CI], 0.53-0.89 and OR, 0.50; 95% CI, 0.31-0.67, respectively). Moreover, -509C-containing <italic>TGFβ1</italic> promoter drove an ~1.7-fold increase in reporter expression, compared with the -509T-containing counterpart in both CNE-1 and CNE-2 cell lines. The <italic>TGFβ1</italic> -509 CC genotype carriers had a higher <italic>TGFβ1</italic> mRNA level than the <italic>TGFβ1</italic> -509TT genotype carriers did (<italic>P</italic> &lt; .01). However, no significant association was observed between the 869T/C polymorphism and risk of NPC.</p>
<p><italic>Conclusion</italic>. These findings indicate that the -509C/T polymorphism in <italic>TGFβ1</italic> may play a vital role in mediating individual susceptibility to NPC.</p>
</abstract>
<kwd-group>
<kwd>nasopharyngeal carcinoma</kwd>
<kwd>TGFβ</kwd>
<kwd>single nucleotide polymorphism</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>The human immune system can create a response against tumor cells, but it is generally ineffective in tumor regression. Several immunosuppressive molecules have been identified.<sup><xref ref-type="bibr" rid="bibr1-0194599811434890">1</xref>-<xref ref-type="bibr" rid="bibr3-0194599811434890">3</xref></sup> Among those, transforming growth factor (TGF)β1 arouses much attention. TGFβ1, secreted and activated by tumor cells, is one of the most potent immunosuppressive molecules known. It down-regulates antitumor immunity. TGFβ1 also promotes tumor development and progression through escape from immunosurveillance. Furthermore, TGFβ1 inhibits the proliferation and functional differentiation of T lymphocytes, lymphokine-activated killer cells, natural killer cells, neutrophils, macrophages, and B cells. TGFβ1 can be induced by Th2 lymphokines such as IL-10,<sup><xref ref-type="bibr" rid="bibr4-0194599811434890">4</xref></sup> and it mediates at least part of the inhibition of immune responses by CD4<sup>+</sup>CD25<sup>+</sup> T cells.<sup><xref ref-type="bibr" rid="bibr5-0194599811434890">5</xref>,<xref ref-type="bibr" rid="bibr6-0194599811434890">6</xref></sup> Prevention of TGFβ1 signaling in T cells can dramatically enhance antitumor immunity to cause tumor rejection.<sup><xref ref-type="bibr" rid="bibr7-0194599811434890">7</xref></sup></p>
<p>TGFβ1 has been found to be associated with many tumors, such as breast cancer, colon cancer, and gastric cancer, in particular.<sup><xref ref-type="bibr" rid="bibr8-0194599811434890">8</xref>-<xref ref-type="bibr" rid="bibr12-0194599811434890">12</xref></sup> Several observations have shown that increased TGFβ1 expression induced tumorigenicity by suppressing local immune response, including prevention of cytotoxic T-lymphocyte activation.<sup><xref ref-type="bibr" rid="bibr7-0194599811434890">7</xref></sup> The human <italic>TGFβ1</italic> gene exhibits sequence variations and several functional single nucleotide polymorphisms (SNPs) in the promoter region, among which the -509C/T (rs1800469) polymorphism is most commonly studied. <italic>TGFβ1</italic> expression is modulated at the level of transcription. Based on the dbSNP database (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</ext-link>), we found there were 3 potential functional SNPs (rs4803455, rs1800469, and rs2317130) in the promoter of <italic>TGFβ1</italic> gene with minor allele frequency &gt;5% in the Chinese population. We then performed bioinformatics analysis with Haploview software 4.2 to analyze the haplotype block based on the Chinese Han Beijing population data of HapMap (HapMap Data Rel 27 PhaseII +III, February 2009, on NCBI B36 assembly, dbSNP b126). We found that the SNP rs1800469 covered 100% frequency of haplotype in the block (rs1800469 and rs4803455: <italic>D</italic>′ = 0.943, <italic>r<sup>2</sup></italic> = 0.651; rs1800469 and rs2317130: <italic>D</italic>′ = 1.0, <italic>r<sup>2</sup></italic> = 0.963). Thus, the SNP rs1800469 might cover the genetic information of common SNPs in the promoter of the <italic>TGFβ1</italic> gene in this study. Another polymorphism, 869T/C (rs1800470), a nonsynonymous mutation, enables substitution of Leu for Pro. It has been suggested that naturally occurring sequence variations in the gene might contribute at least in part to differential expression of <italic>TGFβ1</italic> and a substantial degree of interindividual variability in susceptibility to cancer. Based on previous evidence, we raised the hypothesis that TGFβ1 polymorphisms were associated with an increased risk of nasopharyngeal carcinoma (NPC). To the best of our knowledge, this is the first association study of -509C/T and 869T/C polymorphisms in a Chinese population with large samples.</p>
<sec id="section1-0194599811434890" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="section2-0194599811434890">
<title>Subjects</title>
<p>Five hundred twenty-two newly diagnosed NPC patients and 712 healthy controls were enrolled. All subjects were ethnically homogenous as Han Chinese. All patients were recruited from March 2001 to May 2007, from the Sir Run Run Shaw Hospital, Zhejiang University (Hangzhou) and Zhejiang Cancer Hospital (Hangzhou). All eligible patients diagnosed at the hospital during the study period were recruited, with a response rate of 94%. Patients were from Hangzhou City and its surrounding regions, and there were no age, stage, or histology restrictions.<sup><xref ref-type="bibr" rid="bibr13-0194599811434890">13</xref></sup> Immunoglobulin A antibodies to Epstein-Barr virus (EBV) capsid antigen (EBV/IgA/VCA) and immunoglobulin A antibodies to EBV early antigen were confirmed by serologic testing at the time of study enrollment. The tumor, node, metastasis (TNM) classification and tumor staging was evaluated according to the 2002 American Joint Committee on Cancer staging system.<sup><xref ref-type="bibr" rid="bibr11-0194599811434890">11</xref></sup> The clinical features of the patients are summarized in <bold><xref ref-type="table" rid="table1-0194599811434890">Table 1</xref></bold>. Population controls were cancer-free people living in the Hangzhou region; they were selected from a nutritional survey conducted in the same period as the cases were collected. The control subjects were randomly selected from a database consisting of 2500 individuals based on a physical examination. The selection criteria included no history of cancer and frequency matched to cases on age and sex. The median age was 46 years (range, 26-81 years) for case patients and 47 years (range, 22-85 years) for control subjects (<italic>P</italic> = .78). At recruitment, informed consent was obtained from each subject.<sup><xref ref-type="bibr" rid="bibr14-0194599811434890">14</xref></sup> This study was approved by the Medical Ethics Committee of Sir Run Run Shaw Hospital and Zhejiang Cancer Hospital.</p>
<table-wrap id="table1-0194599811434890" position="float">
<label>Table 1.</label>
<caption><p>Distribution of Selected Characteristics by Case-Control Status in Nasopharyngeal Carcinoma Association Analysis</p></caption>
<graphic alternate-form-of="table1-0194599811434890" xlink:href="10.1177_0194599811434890-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="2">Cases</th>
<th align="center" colspan="2">Controls</th>
</tr>
<tr>
<th/>
<th align="center">n</th>
<th align="center">%</th>
<th align="center">n</th>
<th align="center">%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> Male</td>
<td>315</td>
<td>60.3</td>
<td>404</td>
<td>56.7</td>
</tr>
<tr>
<td> Female</td>
<td>207</td>
<td>39.7</td>
<td>308</td>
<td>42.7</td>
</tr>
<tr>
<td>Age, y</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> ≤40</td>
<td>195</td>
<td>37.4</td>
<td>242</td>
<td>34.0</td>
</tr>
<tr>
<td> 41-50</td>
<td>134</td>
<td>25.7</td>
<td>186</td>
<td>26.1</td>
</tr>
<tr>
<td> 51-60</td>
<td>93</td>
<td>17.8</td>
<td>166</td>
<td>23.3</td>
</tr>
<tr>
<td> &gt;60</td>
<td>100</td>
<td>19.1</td>
<td>118</td>
<td>16.6</td>
</tr>
<tr>
<td>Tumor stage</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> I</td>
<td>126</td>
<td>24.2</td>
<td/>
<td/>
</tr>
<tr>
<td> II</td>
<td>208</td>
<td>39.8</td>
<td/>
<td/>
</tr>
<tr>
<td> III</td>
<td>177</td>
<td>33.9</td>
<td/>
<td/>
</tr>
<tr>
<td> IV</td>
<td>11</td>
<td>2.1</td>
<td/>
<td/>
</tr>
<tr>
<td>Epstein-Barr virus infection status</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> Positive</td>
<td>329</td>
<td>63.1</td>
<td/>
<td/>
</tr>
<tr>
<td> Negative</td>
<td>162</td>
<td>31.0</td>
<td/>
<td/>
</tr>
<tr>
<td> Data missing</td>
<td>31</td>
<td>5.9</td>
<td/>
<td/>
</tr>
<tr>
<td>Metastasis</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> Present</td>
<td>283</td>
<td>54.2</td>
<td/>
<td/>
</tr>
<tr>
<td> Absent</td>
<td>239</td>
<td>45.8</td>
<td/>
<td/>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section3-0194599811434890">
<title>Polymorphism Analysis</title>
<p>Genomic DNA was extracted from a 5-mL peripheral blood sample, which was obtained from patients before they were given chemotherapy or radiotherapy to avoid any influence of these treatments on outcomes. Genotypes were analyzed using PCR-based methods as described below. Genotyping was performed without knowledge of the subject’s case or control status. A 30% masked random sample of cases and controls was tested twice by different people, and the results were concordant for all masked duplicate sets.</p>
<p>The genotypes of <italic>TGFβ1</italic> -509C/T and 869T/C were analyzed by the PCR restriction fragment length polymorphism method on the basis of that reported previously.<sup><xref ref-type="bibr" rid="bibr12-0194599811434890">12</xref></sup> The primers used were -509C/T F, 5′- CAG ACT CTA GAG ACT GTC AG -3′ and R, 5′- GTC ACC AGA GA A AGA GGA C-3′; 869T/C F, 5′- CCT CCC CAC CAC ACC AG -3′ and R, 5′- CGG CAC CTC CCC CTG GCT CG-3′. Amplification was accomplished with a 25-µL reaction mixture containing ~100 ng template DNA, 0.5 µM each primer, 0.2 mM each dNTP, 1.5 mM MgCl<sub>2</sub>, and 1.2 units of <italic>Taq</italic> DNA polymerase with 1× reaction buffer (Promega, Madison, Wisconsin). The PCR profile consisted of an initial melting step of 2 minutes at 94°C, followed by 35 cycles of 30 seconds at 94°C, 30 seconds at 56°C, and 30 seconds at 72°C, and a final elongation step of 7 minutes at 72°C. The PCR products were then subject to the digestion with <italic>Bsu</italic>36I (-509C/T) and <italic>MspAI</italic>I (869T/C, New England Biolabs, UK) and separated on a 3.0% agarose gel.</p>
</sec>
<sec id="section4-0194599811434890">
<title>Construction of Reporter Plasmids</title>
<p>Because the <italic>TGFβ1</italic> -509C/T polymorphism was found to be associated with a significantly increased risk of NPC, we then determined whether this polymorphism had an effect on its gene expression in vitro. The T allelic reporter constructs were prepared by amplifying the 1612-bp <italic>TGFβ1</italic> promoter region (from -1528 to +84 bp relative to the translation start site) from subjects homozygous for the T allele (-509TT), including the artificial <italic>KpnI</italic> and <italic>Hind3</italic> enzymes restriction sites with forward primer 5′-GCC <bold><italic>GGT ACC</italic></bold> TAA TCT GTA GTG CTG CTT CTA-3′ and reverse primer 5′-TGG <bold><italic>AAG CTT</italic></bold> CGC CGG GGA CCC TAC GGG GC-3′. The amplified fragments were then cleaved with the <italic>KpnI</italic> and <italic>Hind3</italic> enzymes (New England BioLabs, Ipswich, Massachusetts). The pGL3 basic vector (Promega) was also cleaved with the <italic>KpnI</italic> and <italic>Hind3</italic> enzymes, and the above-prepared fragment and pGL3 basic vector were then ligated by T4 DNA ligase (New England BioLabs). The p509C reporter constructs were obtained from the p509T constructs by site-directed mutagenesis using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, California). All constructs were sequenced to confirm the allele, the orientation, and integrity of each insert.</p>
</sec>
<sec id="section5-0194599811434890">
<title>Transient Transfections and Luciferase Assays</title>
<p>CNE-1 and CNE-2 cells (transformed human nasopharyngeal carcinoma epithelial cell lines) were grown in RPMI 1640 supplemented with 10% (v/v) heat-inactivated FCS, 2 mmol/L L-glutamine, 100 U/mL penicillin, and 100 U/mL streptomycin at 37°C and 5% CO<sub>2</sub> in a humidified incubator. All cell lines were obtained from China Center for Type Culture Collection. For transient transfection experiments, 5 × 10<sup><xref ref-type="bibr" rid="bibr4-0194599811434890">4</xref></sup> cells were plated in 10-mm 24-multiwell plates and grown to 60% to 70% confluence. Transfection was carried out using LipofectAMINE Reagent (Life Technologies Inc, Rockville, Maryland) according to the manufacturer’s protocol. Cells were co-transfected with 0.5 µg of reporter plasmid (p509C and p509T; <xref ref-type="fig" rid="fig1-0194599811434890"><bold>Figure 1</bold></xref>) and 0.1 µg of pRL-SV40 (Luciferase Assay System; Promega); the latter was used to standardize transfection efficiency. Luciferase activity was determined according to the manufacturer’s protocol using a luciferase assay system (Promega). Briefly, cells were first scraped into lysis reagent, and then the lysate was transferred to microfuge tubes and centrifuged for 30 seconds at 12,000<italic>g</italic> to get the supernatant. Luciferase activity was measured using a manual luminometer (Turner Designs; TD20/20) by mixing 100 µL of luciferase assay reagent with 20 µL of 1:10-diluted cell lysate supernatant, and the value for each sample was recorded 3 times at 10-second intervals. For each plasmid construct, 3 independent transfection experiments were performed, and each was done in triplicate. Results were expressed as a ratio of luciferase activity to pRL-SV40.</p>
<fig id="fig1-0194599811434890" position="float">
<label>Figure 1.</label>
<caption><p>Transient reporter gene expression assays with constructs containing full-length <italic>TGFβ1</italic> promoter. Data shown are the mean fold increase ±SD from 3 independent transfection experiments, each done in triplicate.</p></caption>
<graphic xlink:href="10.1177_0194599811434890-fig1.tif"/>
</fig>
</sec>
<sec id="section6-0194599811434890">
<title>Real-Time Analysis of TGFβ1 mRNA</title>
<p>Total RNA was isolated from 71 NPC tissues using the Trizol reagent (Molecular Research Center Inc, Cincinnati, Ohio) and converted to cDNA using an oligo (dT)<sub>15</sub> primer and Superscript II (Invitrogen, Carlsbad, California). Relative gene expression quantitation for <italic>TGFβ1</italic>, with β<italic>-actin</italic> as an internal reference gene, was carried out using ABI Prism 7300 sequence detection system (Applied Biosystem, Foster City, California) in triplicates, based on the SYBR-Green method.<sup><xref ref-type="bibr" rid="bibr8-0194599811434890">8</xref></sup> The primers used for <italic>TGFβ1</italic> were 5′-TGT AAG TGA ACA TTC AGG TG-3′ and 5′-TTC CAA TAG TCA GCT AAG GA-3′ and for β<italic>-actin</italic> were 5′-GGC GGC ACC ACC ATG TAC CCT-3′ and 5′-AGG GGC CGG ACT CGT CAT ACT- 3′. The PCR reaction mixture consisted of 0.1 µmol/L of each primer, 1 × SYBR Premix EX Taq (Perfect Real Time) premix reagent (TaKaRa, Dalian, China), and 50 ng cDNA to a final volume of 20 µL. Cycling conditions were 95°C for 10 minutes, followed by 40 cycles at 95°C of 15 seconds and 62°C for 1 minute. PCR specificity was confirmed by dissociation curve analysis and gel electrophoresis. All analyses were done in a blinded fashion with the laboratory persons unaware of genotyping data. The expression of individual <italic>TGFβ1</italic> measurements was calculated relative to expression of β<italic>-actin</italic> using a modification of the method described by Lehmann et al.<sup><xref ref-type="bibr" rid="bibr15-0194599811434890">15</xref></sup></p>
</sec>
<sec id="section7-0194599811434890">
<title>Statistical Analysis</title>
<p>χ<sup><xref ref-type="bibr" rid="bibr2-0194599811434890">2</xref></sup> tests were used to examine the differences in the distributions of genotypes between cases and controls. The association between the <italic>TGFβ1</italic> -509C/T and 869T/C polymorphisms and risk of NPC was estimated by odds ratios (ORs) and their 95% confidence intervals (CIs), which were calculated by unconditional logistic regression models adjusted for age and sex. We tested the null hypotheses of multiplicative gene-gene interactions by evaluating departures from multiplicative joint effect models by including main effect variables and their product terms in the logistic regression model.<sup><xref ref-type="bibr" rid="bibr16-0194599811434890">16</xref>-<xref ref-type="bibr" rid="bibr18-0194599811434890">18</xref></sup> A more-than-additive interaction was suggested when OR<sub>11</sub> &gt; OR<sub>10</sub> + OR<sub>01</sub> − 1, for which OR<sub>11</sub> = OR when both factors were present, OR<sub>10</sub> = OR when only factor 1 was present, and OR<sub>01</sub> = OR when only factor 2 was present. A more-than-multiplicative interaction was suggested when OR<sub>11</sub> &gt; OR<sub>10</sub> × OR<sub>01</sub>. The correlation of genotypes and clinical parameters was analyzed via the Fisher exact test or χ<sup><xref ref-type="bibr" rid="bibr2-0194599811434890">2</xref></sup> test as appropriate. The differences in the luciferase reporter activity and normalized expression values in cancer tissue of <italic>TGFβ1</italic> (real-time PCR) between each genotype were analyzed by Kruskal-Wallis 1-way analysis of variance. The tests were all 2-sided and analyzed using SAS software (version 9.1; SAS Institute, Cary, North Carolina). <italic>P</italic> &lt; .05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="section8-0194599811434890" sec-type="results">
<title>Results</title>
<sec id="section9-0194599811434890">
<title>Allele and Genotype Distribution</title>
<p>The genotype results are shown in <bold><xref ref-type="table" rid="table2-0194599811434890">Table 2</xref></bold>. The allele frequencies for -509T and 869C were 0.478 and 0.488 in controls and 0.387 and 0.498 in cases, respectively. The observed genotype frequencies of -509C/T and 869T/C polymorphisms in both controls and cases did not deviate from those expected from the Hardy-Weinberg equilibrium. Distributions of these -509C/T and 869T/C genotypes were then compared among cases and controls. The frequencies of -509 CC, TC, and TT genotypes among patients were significantly different compared with controls (<italic>P<sub>trend</sub></italic> &lt; .001). Moreover, logistic regression analysis showed that subjects with the -509T allele had a significantly reduced risk of NPC compared with subjects carrying the C allele (OR for the CT genotype, 0.67; 95% CI, 0.53-0.89; OR for the TT genotype, 0.50; 95% CI, 0.31-0.67; <italic>P<sub>trend</sub></italic> &lt; .001), suggesting the protective role of the <italic>TGFβ1</italic> -509T allele.</p>
<table-wrap id="table2-0194599811434890" position="float">
<label>Table 2.</label>
<caption><p>Genotype and Allele Frequencies of -509C/T and 869T/C among Patients and Controls and Their Association with the Risk of Nasopharyngeal Carcinoma</p></caption>
<graphic alternate-form-of="table2-0194599811434890" xlink:href="10.1177_0194599811434890-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">Cases (n = 522)</th>
<th align="center">Controls (n = 712)</th>
<th/>
<th/>
</tr>
<tr>
<th align="left">Genotype</th>
<th align="center">n (%)</th>
<th align="center">n (%)</th>
<th align="center">OR<sup><xref ref-type="table-fn" rid="table-fn1-0194599811434890">a</xref></sup> (95% CI)</th>
<th align="center"><italic>P</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td>-509C/T</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> CC</td>
<td>208 (39.8)</td>
<td>203 (28.5)</td>
<td>1.00 (reference)</td>
<td/>
</tr>
<tr>
<td> CT</td>
<td>224 (42.9)</td>
<td>337 (47.3)</td>
<td>0.67 (0.53-0.89)</td>
<td/>
</tr>
<tr>
<td> TT</td>
<td>80 (15.3)</td>
<td>172 (24.2)</td>
<td>0.50 (0.31-0.67)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td> T allele frequency</td>
<td>0.387</td>
<td>0.478</td>
<td/>
<td/>
</tr>
<tr>
<td>869T/C</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> TT</td>
<td>129 (24.7)</td>
<td>187 (26.3)</td>
<td>1.00 (reference)</td>
<td/>
</tr>
<tr>
<td> TC</td>
<td>266 (51.0)</td>
<td>354 (49.7)</td>
<td>1.04 (0.80-1.48)</td>
<td/>
</tr>
<tr>
<td> CC</td>
<td>127 (24.3)</td>
<td>171 (24.0)</td>
<td>1.10 (0.73-1.54)</td>
<td>.64</td>
</tr>
<tr>
<td> C allele frequency</td>
<td>0.498</td>
<td>0.488</td>
<td/>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0194599811434890">
<p><sup>a</sup>Adjusted in a logistic regression model that included age and sex.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>The LD analyses in controls showed that the linkage between the -509C/T locus and 869T/C locus was relatively weak (<italic>D</italic>′ = 0.35, <italic>r<sup>2</sup></italic> = 0.227), suggesting each may have an independent effect on the risk of NPC. The effects of the -509C/T and 869T/C polymorphisms were additionally examined with stratification by age, tumor size, metastatic status, and EBV infection status. However, no significant association was observed between age and the TNM stage at the time of NPC diagnosis and the polymorphism of this gene, and no interaction was detected between the polymorphism and status of EBV infection (data not shown).</p>
</sec>
<sec id="section10-0194599811434890">
<title>Effects of TGFβ1 -509C/T Polymorphism on Transcriptional Activity</title>
<p>To directly determine the transcriptional activity of the <italic>TGFβ1</italic> native promoter, 2 luciferase reporter gene constructs were generated by PCR, spanning -1528 to +84 bp of the <italic>TGFβ1</italic> promoter region, with a T or C at the -509 polymorphic sites, and they were used to transiently transfect 2 NPC cell lines. As shown in <xref ref-type="fig" rid="fig1-0194599811434890"><bold>Figure 1</bold></xref>, we found that the -509C-containing <italic>TGFβ1</italic> promoter drove an ~1.7-fold increased reporter expression compared with the -509T-containing counterpart in both CNE-1 and CNE-2 cell lines.</p>
</sec>
<sec id="section11-0194599811434890">
<title>TGFβ1 RNA Levels in NPC Tissues from Different Genotype Carriers</title>
<p>To examine the effect of the <italic>TGFβ1</italic> -509C/T polymorphism on <italic>TGFβ1</italic> expression in the target tissues, the levels of <italic>TGFβ1</italic> mRNA in individual NPC tissues were quantified by real-time PCR (<xref ref-type="fig" rid="fig2-0194599811434890"><bold>Figure 2</bold></xref>). The results showed that the <italic>TGFβ1</italic> -509 CC genotype carriers had a significantly higher <italic>TGFβ1</italic> mRNA level than the <italic>TGFβ1</italic> -509TT genotype carriers (0.029 ± 0.007 vs 0.008 ± 0.002, <italic>P</italic> &lt; .01).</p>
<fig id="fig2-0194599811434890" position="float">
<label>Figure 2.</label>
<caption><p><italic>TGFβ1</italic> mRNA expression level in NPC tissue. Expression from the -509CC genotype was significantly higher than that of TT genotype (<italic>P</italic> &lt; .01).</p></caption>
<graphic xlink:href="10.1177_0194599811434890-fig2.tif"/>
</fig>
</sec>
</sec>
<sec id="section12-0194599811434890" sec-type="discussion">
<title>Discussion</title>
<p>In this molecular epidemiological study, we found that the <italic>TGFβ1</italic> polymorphism may influence the development of NPC in a Chinese population. On the basis of examining 522 cases and 712 controls, our data showed that the <italic>TGFβ1</italic> -509TT genotype were significantly associated with a reduced risk of NPC, compared with the -509CC genotype. The <italic>TGFβ1</italic> -509TT genotype carriers had a significantly lower <italic>TGFβ1</italic> mRNA level than the <italic>TGFβ1</italic> -509CC genotype carriers did. These findings suggest that the <italic>TGFβ1</italic> -509C/T polymorphism could be used as a genetic susceptibility marker of NPC.</p>
<p>TGFβ1 is the prototype of a family of structurally related polypeptide growth factors.<sup><xref ref-type="bibr" rid="bibr19-0194599811434890">19</xref></sup> The TGFβ1 superfamily members regulate a variety of cellular processes, including growth, differentiation, apoptosis, angiogenesis, extracellular interaction, and immune reactions.<sup><xref ref-type="bibr" rid="bibr19-0194599811434890">19</xref>-<xref ref-type="bibr" rid="bibr21-0194599811434890">21</xref></sup> In mammals, there are 3 isoforms of TGFβ (TGFβ1, TGFβ2, and TGFβ3) that have similar biological properties. Each isoform is encoded by a distinct gene, and each has a tissue-specific expression.<sup><xref ref-type="bibr" rid="bibr22-0194599811434890">22</xref>,<xref ref-type="bibr" rid="bibr23-0194599811434890">23</xref></sup> Of these, TGFβ1 is most frequently upregulated in tumor cells, and it is the focus of most of the studies that have been performed on the role of <italic>TGFβ1</italic> in human cancers. In humans, plasma TGFβ1 levels have been shown to be increased in patients with colorectal cancer,<sup><xref ref-type="bibr" rid="bibr24-0194599811434890">24</xref></sup> prostate cancer,<sup><xref ref-type="bibr" rid="bibr25-0194599811434890">25</xref></sup> and lung cancer.<sup><xref ref-type="bibr" rid="bibr26-0194599811434890">26</xref></sup> Besides, animal and human models suggest that <italic>TGFβ1</italic> can promote tumor progression by facilitating extracellular matrix invasion and angiogenesis.<sup><xref ref-type="bibr" rid="bibr27-0194599811434890">27</xref></sup> In addition, <italic>TGFβ1</italic> might induce tumor progression by inhibiting immune surveillance.<sup><xref ref-type="bibr" rid="bibr28-0194599811434890">28</xref>,<xref ref-type="bibr" rid="bibr29-0194599811434890">29</xref></sup> These observations suggested that the <italic>TGFβ1</italic> gene might be a candidate for cancer. The <italic>TGFβ1</italic> 869T/C polymorphism we investigated here is a nonsynonymous mutation, which changes Leu to Pro. A few studies have investigated the association between the <italic>TGFβ1</italic> polymorphisms and the risk of cancer.<sup><xref ref-type="bibr" rid="bibr30-0194599811434890">30</xref>-<xref ref-type="bibr" rid="bibr33-0194599811434890">33</xref></sup> Lee et al<sup><xref ref-type="bibr" rid="bibr30-0194599811434890">30</xref></sup> have reported that the <italic>TGFβ1</italic> 869C-allele–containing genotypes posed an increased risk for breast cancer (OR, 1.3; 95% CI, 1.02-1.79), especially in postmenopausal women (OR, 1.6; 95% CI, 1.01-2.44). Dunning et al<sup><xref ref-type="bibr" rid="bibr31-0194599811434890">31</xref></sup> have also reported that the <italic>TGFβ1</italic> 869 C-allele–containing genotypes were shown to be associated with increased <italic>TGFβ1</italic> serum level and increased breast cancer risk among C allele carriers with invasive breast cancer in the British and German populations. Jin et al<sup><xref ref-type="bibr" rid="bibr32-0194599811434890">32</xref></sup> reported that there was no apparent relationship of the <italic>TGFβ1</italic> -509C/T and 869T/C polymorphism with the risk of breast cancer in the Finnish and Polish populations. However, in our current study, no significant association was observed between the 869T/C polymorphism and NPC risk. Although it is hard to decipher the reasons for the discrepant findings from different studies, the different genetic backgrounds and different environmental factors, such as the different carcinogens that initiate different cancers and the different carcinogen exposures in different populations, might have caused the different results.</p>
<p>The -509C/T SNP was generally not thought to be part of a known consensus sequence for a promoter regulatory element and therefore unlikely to affect <italic>TGFβ1</italic> expression,<sup><xref ref-type="bibr" rid="bibr31-0194599811434890">31</xref></sup> but one report indicated that it may modify <italic>TGFβ1</italic> expression and affect plasma TGFb1 concentration.<sup><xref ref-type="bibr" rid="bibr34-0194599811434890">34</xref></sup> Analysis of case-control studies is the most prevalent method of investigating the association between a disease and a speciﬁc gene. Thus far, a number of studies have reported a contributory role of the <italic>TGFβ1</italic> -509C/T polymorphism in cancer risk. Jin et al<sup><xref ref-type="bibr" rid="bibr35-0194599811434890">35</xref></sup> found that the -509T allele was significantly associated with a decreased risk of gastric cancer in a Chinese population. Chung et al<sup><xref ref-type="bibr" rid="bibr36-0194599811434890">36</xref></sup> also reported that the -509T allele–containing genotypes posed a reduced risk of colorectal cancer in the Korean population. Despite these aforementioned studies, the exact association between the <italic>TGFβ1</italic> -509C/T polymorphism and the risk of NPC is not clear; therefore, it is necessary to carry out case-control studies with a large sample size in a Chinese population. In addition, the inadequate study design such as nonrandom sampling and a limited sample size should be also considered. The possible selection bias that might have been present in the hospital-based, case-control study is a relevant issue. And the discrepancy might also be attributable to the complexity of the role of TGFβ1. In normal epithelial cells, <italic>TGFβ1</italic> acts as a tumor suppressor by inhibiting cellular proliferation. However, once tumor cells have become resistant to growth inhibition by <italic>TGFβ1</italic>, they become more invasive by <italic>TGFβ1</italic>-mediated stimulation of angiogenesis and cell motility.<sup><xref ref-type="bibr" rid="bibr20-0194599811434890">20</xref>,<xref ref-type="bibr" rid="bibr37-0194599811434890">37</xref></sup></p>
<p>In conclusion, we found that the <italic>TGFβ1</italic> -509C/T polymorphism may affect the expression of TGFβ1 in vivo and then modify the NPC susceptibility in a Chinese population. These results suggest that genetic polymorphisms of <italic>TGFβ1</italic> might be clinically relevant in the development and progression of NPC. However, large-scale, population-based case-control studies, as well as well-designed mechanistic studies, are warranted to validate our findings.</p>
</sec>
<sec id="section13-0194599811434890">
<title>Author Contributions</title>
<p><bold>Sunhong Hu</bold>, performed the statistical analyses and RT-PCR; <bold>Guojin Zhou</bold>, performed luciferase assays; <bold>Lei Zhang</bold>, performed population investigation; <bold>Huifen Jiang</bold>, performed the genotypes; <bold>Mang Xiao</bold>, designed the study.</p>
</sec>
<sec id="section14-0194599811434890">
<title>Disclosures</title>
<p><bold>Competing interests:</bold> None.</p>
<p><bold>Sponsorships:</bold> The project was supported by Zhejiang Provincial Natural Science Foundation of China.</p>
<p><bold>Funding source:</bold> Chinese government. The work was supported by grants from the Zhejiang Provincial Natural Science Foundation of China (Y2100449 and Y2110410) and the Foundation of Zhejiang Educational Committee (ZC200803926).</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="presented-at">
<p>Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0194599811434890">
<citation citation-type="journal">
<label>1.</label>
<person-group person-group-type="author">
<name><surname>Kiessling</surname><given-names>R</given-names></name>
<name><surname>Wasserman</surname><given-names>K</given-names></name>
<name><surname>Horiguchi</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Tumor-induced immune dysfunction</article-title>. <source>Cancer Immunol Immunother</source>. <year>1999</year>;<volume>48</volume>: <fpage>353</fpage>-<lpage>362</lpage>.</citation>
</ref> <ref id="bibr2-0194599811434890">
<citation citation-type="journal">
<label>2.</label>
<person-group person-group-type="author">
<name><surname>Hellstrom</surname><given-names>KE</given-names></name>
<name><surname>Hellstrom</surname><given-names>I.</given-names></name>
</person-group> <article-title>Novel approaches to therapeutic cancer vaccines</article-title>. <source>Expert Rev Vaccines</source>. <year>2003</year>;<volume>2</volume>:<fpage>517</fpage>-<lpage>532</lpage>.</citation>
</ref>
<ref id="bibr3-0194599811434890">
<citation citation-type="journal">
<label>3.</label>
<person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>J</given-names></name>
<name><surname>Yu</surname><given-names>X</given-names></name>
<name><surname>Jiang</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Association between the cytotoxic T-lymphocyte antigen 4 +49G &gt; A polymorphism and cancer risk: a meta-analysis</article-title>. <source>BMC Cancer</source>. <year>2010</year>;<volume>10</volume>:<fpage>522</fpage>.</citation>
</ref>
<ref id="bibr4-0194599811434890">
<citation citation-type="journal">
<label>4.</label>
<person-group person-group-type="author">
<name><surname>D’Orazio</surname><given-names>TJ</given-names></name>
<name><surname>Niederkorn</surname><given-names>JY</given-names></name>
</person-group>. <article-title>A novel role for TGF-beta and IL-10 in the induction of immune privilege</article-title>. <source>J Immunol</source>. <year>1998</year>;<volume>160</volume>:<fpage>2089</fpage>-<lpage>2098</lpage>.</citation>
</ref>
<ref id="bibr5-0194599811434890">
<citation citation-type="journal">
<label>5.</label>
<person-group person-group-type="author">
<name><surname>Nakamura</surname><given-names>K</given-names></name>
<name><surname>Kitani</surname><given-names>A</given-names></name>
<name><surname>Strober</surname><given-names>W</given-names></name>
</person-group>. <article-title>Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta</article-title>. <source>J Exp Med</source>. <year>2001</year>;<volume>194</volume>:<fpage>629</fpage>-<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr6-0194599811434890">
<citation citation-type="journal">
<label>6.</label>
<person-group person-group-type="author">
<name><surname>Liyanage</surname><given-names>UK</given-names></name>
<name><surname>Moore</surname><given-names>TT</given-names></name>
<name><surname>Joo</surname><given-names>HG</given-names></name>
<etal/>
</person-group>. <article-title>Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma</article-title>. <source>J Immunol</source>. <year>2002</year>;<volume>169</volume>:<fpage>2756</fpage>-<lpage>2761</lpage>.</citation>
</ref>
<ref id="bibr7-0194599811434890">
<citation citation-type="journal">
<label>7.</label>
<person-group person-group-type="author">
<name><surname>Kanamaru</surname><given-names>Y</given-names></name>
<name><surname>Nakao</surname><given-names>A</given-names></name>
<name><surname>Mamura</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Blockade of TGF-beta signaling in T cells prevents the development of experimental glomerulonephritis</article-title>. <source>J Immunol</source>. <year>2001</year>;<volume>166</volume>:<fpage>2818</fpage>-<lpage>2823</lpage>.</citation>
</ref>
<ref id="bibr8-0194599811434890">
<citation citation-type="journal">
<label>8.</label>
<person-group person-group-type="author">
<name><surname>Dickson</surname><given-names>RB</given-names></name>
<name><surname>Kasid</surname><given-names>A</given-names></name>
<name><surname>Huff</surname><given-names>KK</given-names></name>
<etal/>
</person-group>. <article-title>Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 beta-estradiol or v-Ha-ras oncogene</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1987</year>;<volume>84</volume>:<fpage>837</fpage>-<lpage>841</lpage>.</citation>
</ref>
<ref id="bibr9-0194599811434890">
<citation citation-type="journal">
<label>9.</label>
<person-group person-group-type="author">
<name><surname>Lu</surname><given-names>SL</given-names></name>
<name><surname>Zhang</surname><given-names>WC</given-names></name>
<name><surname>Akiyama</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>Genomic structure of the transforming growth factor beta type II receptor gene and its mutations in hereditary nonpolyposis colorectal cancers</article-title>. <source>Cancer Res</source>. <year>1996</year>;<volume>56</volume>:<fpage>4595</fpage>-<lpage>4598</lpage>.</citation>
</ref>
<ref id="bibr10-0194599811434890">
<citation citation-type="journal">
<label>10.</label>
<person-group person-group-type="author">
<name><surname>Park</surname><given-names>K</given-names></name>
<name><surname>Kim</surname><given-names>SJ</given-names></name>
<name><surname>Bang</surname><given-names>YJ</given-names></name>
<etal/>
</person-group>. <article-title>Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1994</year>;<volume>91</volume>:<fpage>8772</fpage>-<lpage>8776</lpage>.</citation>
</ref>
<ref id="bibr11-0194599811434890">
<citation citation-type="journal">
<label>11.</label>
<person-group person-group-type="author">
<name><surname>Chung</surname><given-names>YJ</given-names></name>
<name><surname>Song</surname><given-names>JM</given-names></name>
<name><surname>Lee</surname><given-names>JY</given-names></name>
<etal/>
</person-group>. <article-title>Microsatellite instability-associated mutations associate preferentially with the intestinal type of primary gastric carcinomas in a high-risk population</article-title>. <source>Cancer Res</source>. <year>1996</year>;<volume>56</volume>:<fpage>4662</fpage>-<lpage>4665</lpage>.</citation>
</ref>
<ref id="bibr12-0194599811434890">
<citation citation-type="journal">
<label>12.</label>
<person-group person-group-type="author">
<name><surname>Izumoto</surname><given-names>S</given-names></name>
<name><surname>Arita</surname><given-names>N</given-names></name>
<name><surname>Ohnishi</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Microsatellite instability and mutated type II transforming growth factor-beta receptor gene in gliomas</article-title>. <source>Cancer Lett</source>. <year>1997</year>;<volume>112</volume>:<fpage>251</fpage>-<lpage>256</lpage>.</citation>
</ref>
<ref id="bibr13-0194599811434890">
<citation citation-type="journal">
<label>13.</label>
<person-group person-group-type="author">
<name><surname>Xiao</surname><given-names>M</given-names></name>
<name><surname>Qi</surname><given-names>F</given-names></name>
<name><surname>Chen</surname><given-names>X</given-names></name>
<etal/>
</person-group>. <article-title>Functional polymorphism of cytotoxic T-lymphocyte antigen 4 and nasopharyngeal carcinoma susceptibility in a Chinese population</article-title>. <source>Int J Immunogenet</source>. <year>2010</year>;<volume>37</volume>:<fpage>27</fpage>-<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr14-0194599811434890">
<citation citation-type="journal">
<label>14.</label>
<person-group person-group-type="author">
<name><surname>Xiao</surname><given-names>M</given-names></name>
<name><surname>Zhang</surname><given-names>L</given-names></name>
<name><surname>Zhu</surname><given-names>X</given-names></name>
<etal/>
</person-group>. <article-title>Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population</article-title>. <source>BMC Cancer</source>. <year>2010</year>;<volume>10</volume>:<fpage>147</fpage>.</citation>
</ref>
<ref id="bibr15-0194599811434890">
<citation citation-type="journal">
<label>15.</label>
<person-group person-group-type="author">
<name><surname>Lehmann</surname><given-names>T</given-names></name>
<name><surname>Biernacka-Lukanty</surname><given-names>J</given-names></name>
<name><surname>Trzeciak</surname><given-names>WH</given-names></name>
</person-group>. <article-title>Expression of three negative regulators of CYP17 gene transcription in adrenocortical cells</article-title>. <source>Endocr Res</source>. <year>2000</year>;<volume>26</volume>:<fpage>1019</fpage>-<lpage>1026</lpage>.</citation>
</ref>
<ref id="bibr16-0194599811434890">
<citation citation-type="journal">
<label>16.</label>
<person-group person-group-type="author">
<name><surname>Jiang</surname><given-names>L</given-names></name>
<name><surname>Zhang</surname><given-names>C</given-names></name>
<name><surname>Li</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>A non-synonymous polymorphism Thr115Met in the EpCAM gene is associated with an increased risk of breast cancer in Chinese population</article-title>. <source>Breast Cancer Res Treat</source>. <year>2011</year>;<volume>126</volume>:<fpage>487</fpage>-<lpage>495</lpage>.</citation>
</ref>
<ref id="bibr17-0194599811434890">
<citation citation-type="journal">
<label>17.</label>
<person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>J</given-names></name>
<name><surname>Liu</surname><given-names>B</given-names></name>
<name><surname>Zhang</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>The protective role of polymorphism MKK4 -1304 T&gt;G in nasopharyngeal carcinoma is modulated by Epstein-Barr virus infection status [published online ahead of print June 23, 2011]</article-title>. <source>Int J Cancer</source>. doi: 10.1002/ijc.26253<pub-id pub-id-type="doi">10.1002/ijc.26253</pub-id>.</citation>
</ref>
<ref id="bibr18-0194599811434890">
<citation citation-type="journal">
<label>18.</label>
<person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>J</given-names></name>
<name><surname>Zhang</surname><given-names>C</given-names></name>
<name><surname>Jiang</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Functional NBS1 polymorphism is associated with occurrence and advanced disease status of nasopharyngeal carcinoma</article-title>. <source>Mol Carcinog</source>. <year>2011</year>;<volume>50</volume>:<fpage>689</fpage>-<lpage>696</lpage>.</citation>
</ref>
<ref id="bibr19-0194599811434890">
<citation citation-type="journal">
<label>19.</label>
<person-group person-group-type="author">
<name><surname>Piek</surname><given-names>E</given-names></name>
<name><surname>Heldin</surname><given-names>CH</given-names></name>
<name><surname>Ten Dijke</surname><given-names>P.</given-names></name>
</person-group>
<article-title>Specificity, diversity, and regulation in TGF-beta superfamily signaling</article-title>. <source>FASEB J</source>. <year>1999</year>;<volume>13</volume>:<fpage>2105</fpage>-<lpage>2124</lpage>.</citation>
</ref>
<ref id="bibr20-0194599811434890">
<citation citation-type="journal">
<label>20.</label>
<person-group person-group-type="author">
<name><surname>Elliott</surname><given-names>RL</given-names></name>
<name><surname>Blobe</surname><given-names>GC</given-names></name>
</person-group>. <article-title>Role of transforming growth factor Beta in human cancer</article-title>. <source>J Clin Oncol</source>. <year>2005</year>;<volume>23</volume>:<fpage>2078</fpage>-<lpage>2093</lpage>.</citation>
</ref>
<ref id="bibr21-0194599811434890">
<citation citation-type="journal">
<label>21.</label>
<person-group person-group-type="author">
<name><surname>Mishra</surname><given-names>L</given-names></name>
<name><surname>Derynck</surname><given-names>R</given-names></name>
<name><surname>Mishra</surname><given-names>B.</given-names></name>
</person-group>
<article-title>Transforming growth factor-beta signaling in stem cells and cancer</article-title>. <source>Science</source>. <year>2005</year>;<volume>310</volume>:<fpage>68</fpage>-<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr22-0194599811434890">
<citation citation-type="journal">
<label>22.</label>
<person-group person-group-type="author">
<name><surname>Roberts</surname><given-names>AB</given-names></name>
<name><surname>Sporn</surname><given-names>MB</given-names></name>
</person-group>. <article-title>Differential expression of the TGF-beta isoforms in embryogenesis suggests specific roles in developing and adult tissues</article-title>. <source>Mol Reprod Dev</source>. <year>1992</year>;<volume>32</volume>:<fpage>91</fpage>-<lpage>98</lpage>.</citation>
</ref>
<ref id="bibr23-0194599811434890">
<citation citation-type="journal">
<label>23.</label>
<person-group person-group-type="author">
<name><surname>Attisano</surname><given-names>L</given-names></name>
<name><surname>Wrana</surname><given-names>JL</given-names></name>
</person-group>. <article-title>Signal transduction by the TGF-beta superfamily</article-title>. <source>Science</source>. <year>2002</year>;<volume>296</volume>:<fpage>1646</fpage>-<lpage>1647</lpage>.</citation>
</ref>
<ref id="bibr24-0194599811434890">
<citation citation-type="journal">
<label>24.</label>
<person-group person-group-type="author">
<name><surname>Tsushima</surname><given-names>H</given-names></name>
<name><surname>Ito</surname><given-names>N</given-names></name>
<name><surname>Tamura</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Circulating transforming growth factor beta 1 as a predictor of liver metastasis after resection in colorectal cancer</article-title>. <source>Clin Cancer Res</source>. <year>2001</year>;<volume>7</volume>:<fpage>1258</fpage>-<lpage>1262</lpage>.</citation>
</ref>
<ref id="bibr25-0194599811434890">
<citation citation-type="journal">
<label>25.</label>
<person-group person-group-type="author">
<name><surname>Shariat</surname><given-names>SF</given-names></name>
<name><surname>Kattan</surname><given-names>MW</given-names></name>
<name><surname>Traxel</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression</article-title>. <source>Clin Cancer Res</source>. <year>2004</year>;<volume>10</volume>:<fpage>1992</fpage>-<lpage>1999</lpage>.</citation>
</ref>
<ref id="bibr26-0194599811434890">
<citation citation-type="journal">
<label>26.</label>
<person-group person-group-type="author">
<name><surname>Domagala-Kulawik</surname><given-names>J</given-names></name>
<name><surname>Hoser</surname><given-names>G</given-names></name>
<name><surname>Safianowska</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Elevated TGF-beta1 concentration in bronchoalveolar lavage fluid from patients with primary lung cancer</article-title>. <source>Arch Immunol Ther Exp (Warsz)</source>. <year>2006</year>;<volume>54</volume>:<fpage>143</fpage>-<lpage>147</lpage>.</citation>
</ref>
<ref id="bibr27-0194599811434890">
<citation citation-type="journal">
<label>27.</label>
<person-group person-group-type="author">
<name><surname>Wright</surname><given-names>JA</given-names></name>
<name><surname>Turley</surname><given-names>EA</given-names></name>
<name><surname>Greenberg</surname><given-names>AH</given-names></name>
</person-group>. <article-title>Transforming growth factor beta and fibroblast growth factor as promoters of tumor progression to malignancy</article-title>. <source>Crit Rev Oncog</source>. <year>1993</year>;<volume>4</volume>:<fpage>473</fpage>-<lpage>492</lpage>.</citation>
</ref>
<ref id="bibr28-0194599811434890">
<citation citation-type="journal">
<label>28.</label>
<person-group person-group-type="author">
<name><surname>Wojtowicz-Praga</surname><given-names>S.</given-names></name>
</person-group>
<article-title>Reversal of tumor-induced immunosuppression: a new approach to cancer therapy</article-title>. <source>J Immunother</source>. <year>1997</year>;<volume>20</volume>:<fpage>165</fpage>-<lpage>177</lpage>.</citation>
</ref>
<ref id="bibr29-0194599811434890">
<citation citation-type="journal">
<label>29.</label>
<person-group person-group-type="author">
<name><surname>Mocellin</surname><given-names>S</given-names></name>
<name><surname>Wang</surname><given-names>E</given-names></name>
<name><surname>Marincola</surname><given-names>FM</given-names></name>
</person-group>. <article-title>Cytokines and immune response in the tumor microenvironment</article-title>. <source>J Immunother</source>. <year>2001</year>;<volume>24</volume>:<fpage>392</fpage>-<lpage>407</lpage>.</citation>
</ref>
<ref id="bibr30-0194599811434890">
<citation citation-type="journal">
<label>30.</label>
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>KM</given-names></name>
<name><surname>Park</surname><given-names>SK</given-names></name>
<name><surname>Hamajima</surname><given-names>N</given-names></name>
<etal/>
</person-group>. <article-title>Genetic polymorphisms of TGF-beta1 &amp; TNF-beta and breast cancer risk</article-title>. <source>Breast Cancer Res Treat</source>. <year>2005</year>;<volume>90</volume>:<fpage>149</fpage>-<lpage>155</lpage>.</citation>
</ref>
<ref id="bibr31-0194599811434890">
<citation citation-type="journal">
<label>31.</label>
<person-group person-group-type="author">
<name><surname>Dunning</surname><given-names>AM</given-names></name>
<name><surname>Ellis</surname><given-names>PD</given-names></name>
<name><surname>McBride</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer</article-title>. <source>Cancer Res</source>. <year>2003</year>;<volume>63</volume>:<fpage>2610</fpage>-<lpage>2615</lpage>.</citation>
</ref>
<ref id="bibr32-0194599811434890">
<citation citation-type="journal">
<label>32.</label>
<person-group person-group-type="author">
<name><surname>Jin</surname><given-names>Q</given-names></name>
<name><surname>Hemminki</surname><given-names>K</given-names></name>
<name><surname>Grzybowska</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>Polymorphisms and haplotype structures in genes for transforming growth factor beta1 and its receptors in familial and unselected breast cancers</article-title>. <source>Int J Cancer</source>. <year>2004</year>;<volume>112</volume>:<fpage>94</fpage>-<lpage>99</lpage>.</citation>
</ref>
<ref id="bibr33-0194599811434890">
<citation citation-type="journal">
<label>33.</label>
<person-group person-group-type="author">
<name><surname>Hishida</surname><given-names>A</given-names></name>
<name><surname>Iwata</surname><given-names>H</given-names></name>
<name><surname>Hamajima</surname><given-names>N</given-names></name>
<etal/>
</person-group>. <article-title>Transforming growth factor B1 T29C polymorphism and breast cancer risk in Japanese women</article-title>. <source>Breast Cancer</source>. <year>2003</year>;<volume>10</volume>:<fpage>63</fpage>-<lpage>69</lpage>.</citation>
</ref>
<ref id="bibr34-0194599811434890">
<citation citation-type="journal">
<label>34.</label>
<person-group person-group-type="author">
<name><surname>Grainger</surname><given-names>DJ</given-names></name>
<name><surname>Heathcote</surname><given-names>K</given-names></name>
<name><surname>Chiano</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Genetic control of the circulating concentration of transforming growth factor type beta1</article-title>. <source>Hum Mol Genet</source>. <year>1999</year>;<volume>8</volume>:<fpage>93</fpage>-<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr35-0194599811434890">
<citation citation-type="journal">
<label>35.</label>
<person-group person-group-type="author">
<name><surname>Jin</surname><given-names>G</given-names></name>
<name><surname>Wang</surname><given-names>L</given-names></name>
<name><surname>Chen</surname><given-names>W</given-names></name>
<etal/>
</person-group>. <article-title>Variant alleles of TGFB1 and TGFBR2 are associated with a decreased risk of gastric cancer in a Chinese population</article-title>. <source>Int J Cancer</source>. <year>2007</year>;<volume>120</volume>:<fpage>1330</fpage>-<lpage>1335</lpage>.</citation>
</ref>
<ref id="bibr36-0194599811434890">
<citation citation-type="journal">
<label>36.</label>
<person-group person-group-type="author">
<name><surname>Chung</surname><given-names>SJ</given-names></name>
<name><surname>Kim</surname><given-names>JS</given-names></name>
<name><surname>Jung</surname><given-names>HC</given-names></name>
<etal/>
</person-group>. <article-title>Transforming growth factor-[beta]1 -509T reduces risk of colorectal cancer, but not adenoma in Koreans</article-title>. <source>Cancer Sci</source>. <year>2007</year>;<volume>98</volume>:<fpage>401</fpage>-<lpage>404</lpage>.</citation>
</ref>
<ref id="bibr37-0194599811434890">
<citation citation-type="journal">
<label>37.</label>
<person-group person-group-type="author">
<name><surname>de Caestecker</surname><given-names>MP</given-names></name>
<name><surname>Piek</surname><given-names>E</given-names></name>
<name><surname>Roberts</surname><given-names>AB</given-names></name>
</person-group>. <article-title>Role of transforming growth factor-beta signaling in cancer</article-title>. <source>J Natl Cancer Inst</source>. <year>2000</year>;<volume>92</volume>:<fpage>1388</fpage>-<lpage>1402</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>